JAPANESE TOP Message from the Director Information Faculty list Research Cooperative Research Projects Entrance Exam Publication Job Vacancy INTERNSHIP PROGRAM Links Access HANDBOOK FOR INTERNATIONAL RESEARCHERS Map of Inuyama
BONOBO Chimpanzee "Ai" Crania photos Itani Jun'ichiro archives Open datasets for behavioral analysis Guidelines for Care and Use of Nonhuman Primates(pdf) Study material catalogue/database Guideline for field research of non-human primates 2019(pdf) Primate Genome DB

Primate Research Institute, Kyoto University
Inuyama, Aichi 484-8506, JAPAN
TEL. +81-568-63-0567
(Administrative Office)
FAX. +81-568-63-0085

Copyright (c)
Primate Research Institute,
Kyoto University All rights reserved.



The Novel PKC Activator 10-Methyl-Aplog-1 Combined with JQ1 Induced Strong and Synergistic HIV Reactivation with Tolerable Global T Cell Activation
Ayaka Washizaki, Megumi Murata, Yohei Seki, Masayuki Kikumori, Yinpui Tang, Weikeat Tan, Nadita P. Wardani, Kazuhiro Irie and Hirofumi Akari

The presence of latent human immunodeficiency virus (HIV) reservoirs is a major obstacle to a cure. The "shock and kill" therapy is based on the concept that latent reservoirs in HIV carriers with antiretroviral therapy are reactivated by latency-reversing agents (LRAs), followed by elimination due to HIV-associated cell death or killing by virus-specific cytotoxic T lymphocytes. Protein kinase C (PKC) activators are considered robust LRAs as they efficiently reactivate latently infected HIV. However, various adverse events hamper the intervention trial of PKC activators as LRAs. We found in this study that a novel PKC activator, 10-Methyl-aplog-1 (10MA-1), combined with an inhibitor of bromodomain and extra-terminal domain motifs, JQ1, strongly and synergistically reactivated latently infected HIV. Notably, higher concentrations of 10MA-1 alone induced the predominant side effect, i.e., global T cell activation as defined by CD25 expression and pro-inflammatory cytokine production in primary CD4+ T lymphocytes; however, JQ1 efficiently suppressed the 10MA-1-induced side effect in a dose-dependent manner. Considering the reasonable accessibility and availability of 10MA-1 since the chemical synthesis of 10MA-1 requires fewer processes than that of bryostatin 1 or prostratin, our results suggest that the combination of 10MA-1 with JQ1 may be a promising pair of LRAs for the clinical application of the "shock and kill" therapy.
Bibliographic information

Viruses 2021, 13(10), 2037

2021/10/15 Primate Research Institute